Kyverna Therapeutics

Stories

Kyverna touts year-long miv-cel data as Novartis, Bristol Myers pause autoimmune CAR-T trials

As of September 2026: Filing for FDA approval of miv-cel in stiff person syndrome

Novartis paused its autoimmune CAR-T trials this month after three patients died from a severe immune reaction, and Bristol Myers paused its own over similar inflammatory events. The same week, Kyverna Therapeutics released 12 months of follow-up data on miv-cel, its rival therapy, reporting sustained improvement in stiff person syndrome patients with no high-grade immune toxicity.

Updated Sep 24